- Edwards Lifesciences (NYSE:EW -0.2%) announces that its SAPIEN 3 Ultra transcatheter aortic valve used to treat severe symptomatic aortic stenosis is now CE Mark certified.
- The company says the device has enhanced features compared to SAPIEN 3, including a heightened outer skirt to eliminate leaking around the valve, and an improved delivery system.
- Commercial launch in Germany will be postponed until a patent dispute with Boston Scientific is resolved.
- Previously: Boston Scientific prevails over Edwards Lifesciences in Sapien 3 patent dispute in Germany (Oct. 23)
Edwards Lifesciences' SAPIEN 3 Ultra valve CE Mark'd
Recommended For You
More Trending News
About EW Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
EW | - | - |
Edwards Lifesciences Corporation |